safety-pharmacologist

What problem does it solve?

This Skill prevents unsafe OM (oral mucositis) drug candidates from being advanced by identifying toxicity risks, clinically relevant drug-drug interactions, and cancer-treatment compatibility concerns for immunocompromised patients.

Core Features & Use Cases

• Immunocompromised toxicity screening: Assesses hepatic, cardiac (QT), renal, hematologic, GI, neurologic, immune, and topical-application risks with OM-specific nuance (damaged mucosa increases systemic exposure).
• Drug-drug interaction (DDI) risk analysis: Evaluates CYP-mediated interactions, P-gp-related liability, QT-prolongation combinations, and pharmacodynamic interaction hazards (bleeding, immunosuppression, organ toxicity stacking).
• Cancer treatment interference guardrails: Flags candidate mechanisms that could reduce radiation/chemo/immunotherapy efficacy (notably systemic ROS-interference, immunosuppression, MDR/P-gp induction, and tumor cytoprotection concerns).
• Natural product quality/safety review: Prioritizes contamination (e.g., heavy metals), batch variability, adulteration, allergy/estrogenic effects, and photosensitization—then translates findings into a decision-ready verdict.

Quick Start

Use the safety-pharmacologist skill to produce a structured safety assessment and GREEN/YELLOW/ORANGE/RED/BLACK verdict for a specific candidate compound against immunocompromised OM patients.